Vandria launches to treat age-related diseases

Vandria has launched with $20.6 million in series A funding to develop small-molecule mitophagy inducers. Vandia, which spun out of the Swiss firm Amazentis, will develop compounds to treat age-related and chronic muscle, lung, and liver diseases. The new firm already has a lead candidate, VNA-318, for improving memory and learning; it will enter clinical trials this year.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Posts